Phase I results move Alzheimer’s candidate drug aducanumab into phase III trialsDecember 19, 2016NeurologyGeriatrics
Lack of natalizumab concentration increase before PML argues against extending dosing intervalDecember 14, 2016Neurology
Sigma-1 agonist presses forward after positive results in small Alzheimer’s trialDecember 13, 2016NeurologyGeriatrics
Two-test sequence identifies sporadic Creutzfeldt-Jakob with 100% sensitivity, specificityDecember 12, 2016Rare DiseasesNeurology
TauRx still rooting for its methylene blue AD drug, despite controversial study resultsDecember 10, 2016NeurologyGeriatrics
After full data release, experts say failed Alzheimer’s trial EXPEDITION 3 offers hopeful signalsDecember 9, 2016NeurologyGeriatrics
One in three older adults with epilepsy has poor adherence to antiepilepticsDecember 6, 2016NeurologyGeriatrics
